BRCA1 and ovarian cancer: Therefore, there were speculations that PARP inhibitors may benefit patients with ovarian cancer without a genetic mutation (BRCA1/2 mutation or HRD mutation) for two reasons [37]: (1) the role of PARP-1-RNA interactions in the nucleoli and (2) the role of PARP-1 in site-specific modification of protein substrates in ribosome biogenesis.